Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

NARecruitingINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2027

Conditions
Prostate Cancer
Interventions
RADIATION

1.5 T Elekta Unity MR-Linac system

Patients will receive 9 Gy/fraction (45 Gy total) for five fractions to the DIL, while the remainder of the prostate will be treated to 30 Gy in 5 fractions.

DEVICE

Hydrogel rectal spacer (SpaceOAR)

A rectal spacer will be placed one week prior to simulation to achieve a separation of approximately 1 cm between the prostate and anterior rectal wall to further minimize rectal toxicity in these patients. The hydrogel will remain in the body for about 12 weeks.

Trial Locations (1)

10016

RECRUITING

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER